ALEC
VENTE TOTALE: 72 606 titres (~193 473,21 $ US)
- Insiders
- Rosenthal Arnon
- Total bought
- —
- Total sold
- $193,473
- Last activity
- 2026-09-03
- Last synced
-
2026-09-09 09:58:02
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-09
ALEC presents a deeply unfavorable risk profile, combining severe financial distress (liquidity score: 45, fundamentals trend score: 15) with a strongly negative catalyst backdrop (catalyst score: 15).
The first sentence of the analysis written for ALEC on 2026-09-09 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 54.1% | -84.9% | 90.9% | 100.0% | 8.5% | |
| Ebit Margin | -678.4% | -118.3% | -129.0% | -97.3% | -17.5% | |
| Ebitda Margin | -632.5% | -109.5% | -119.9% | -91.0% | -13.5% | |
| Operating Profit Margin | -692.8% | -144.2% | -156.3% | -103.2% | -18.0% | |
| Pretax Profit Margin | -678.4% | -118.3% | -129.0% | -97.3% | -17.5% | |
| Continuous Operations Profit Margin | -679.2% | -118.4% | -134.3% | -99.8% | -17.5% | |
| Net Profit Margin | -679.2% | -118.4% | -134.3% | -99.8% | -17.5% | |
| Bottom Line Profit Margin | -679.2% | -118.4% | -134.3% | -99.8% | -17.5% | |
| Current Ratio | 3.834 | 3.397 | 3.180 | 7.744 | 5.372 | |
| Quick Ratio | 3.834 | 3.397 | 3.180 | 7.744 | 5.372 | |
| Solvency Ratio | -0.508 | -0.323 | -0.249 | -0.218 | -0.055 | |
| Cash Ratio | 0.947 | 0.264 | 0.419 | 1.645 | 2.359 | |
| Price To Earnings Ratio | -1.122 | -1.537 | -5.115 | -5.698 | -45.889 | |
| Price To Earnings Growth Ratio | -0.086 | 0.073 | 1.381 | -0.022 | 0.562 | |
| Forward Price To Earnings Growth Ratio | -0.086 | 0.073 | 1.381 | -0.022 | 0.562 | |
| Price To Earnings Diluted Ratio | -1.122 | -1.537 | -5.115 | -5.698 | -45.889 | |
| Price To Earnings Diluted Growth Ratio | -0.086 | 0.073 | 1.381 | -0.022 | 0.562 | |
| Price To Book Ratio | 5.243 | 1.440 | 4.981 | 3.550 | 5.522 | |
| Price To Sales Ratio | 7.635 | 1.815 | 6.884 | 5.697 | 8.019 | |
| Price To Free Cash Flow Ratio | -0.873 | -0.790 | -3.582 | -31.137 | 5.623 | |
| Price To Operating Cash Flow Ratio | -0.873 | -0.794 | -3.628 | -37.443 | 5.562 | |
| Debt To Assets Ratio | 0.124 | 0.091 | 0.063 | 0.055 | 0.058 | |
| Debt To Equity Ratio | 1.182 | 0.335 | 0.290 | 0.202 | 0.158 | |
| Debt To Capital Ratio | 0.542 | 0.251 | 0.225 | 0.168 | 0.137 | |
| Long Term Debt To Capital Ratio | 0.233 | 0.069 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 9.568 | 3.693 | 4.635 | 3.673 | 2.709 | |
| Working Capital Turnover Ratio | 0.085 | 0.292 | 0.190 | 0.215 | 0.430 | |
| Operating Cash Flow Ratio | -2.648 | -1.838 | -1.035 | -0.217 | 2.139 | |
| Operating Cash Flow Sales Ratio | -8.745 | -2.286 | -1.897 | -0.152 | 1.442 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.005 | 1.013 | 1.203 | 0.989 | |
| Debt Service Coverage Ratio | -364.120 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -502.817 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -5.079 | -5.407 | -4.732 | -0.469 | 6.272 | |
| Capital Expenditure Coverage Ratio | -4,488.561 | -183.191 | -77.346 | -4.938 | 91.947 | |
| Dividend Paid And Capex Coverage Ratio | -4,488.561 | -183.191 | -77.346 | -4.938 | 91.947 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -0.985 | -1.745 | -5.438 | -5.348 | -49.227 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 54.1% | ▲139.0% | ▲20.4% |
| Ebit Margin | -678.4% | ▼-560.1% | ▼-470.3% |
| Ebitda Margin | -632.4% | ▼-523.0% | ▼-439.2% |
| Operating Profit Margin | -692.8% | ▼-548.6% | ▼-469.9% |
| Pretax Profit Margin | -678.4% | ▼-560.1% | ▼-470.3% |
| Continuous Operations Profit Margin | -679.2% | ▼-560.8% | ▼-469.3% |
| Net Profit Margin | -679.2% | ▼-560.8% | ▼-469.3% |
| Bottom Line Profit Margin | -679.2% | ▼-560.8% | ▼-469.3% |
| Current Ratio | 3.834 | ▲0.437 | ▼-0.872 |
| Quick Ratio | 3.834 | ▲0.437 | ▼-0.872 |
| Solvency Ratio | -0.507 | ▼-0.185 | ▼-0.237 |
| Cash Ratio | 0.947 | ▲0.683 | ▼-0.180 |
| Price To Earnings Ratio | -1.122 | ▲0.414 | ▲10.750 |
| Price To Earnings Growth Ratio | -0.086 | ▼-0.159 | ▼-0.468 |
| Forward Price To Earnings Growth Ratio | -0.086 | ▼-0.159 | ▼-0.468 |
| Price To Earnings Diluted Ratio | -1.122 | ▲0.414 | ▲10.750 |
| Price To Earnings Diluted Growth Ratio | -0.086 | ▼-0.159 | ▼-0.468 |
| Price To Book Ratio | 5.242 | ▲3.803 | ▲1.096 |
| Price To Sales Ratio | 7.635 | ▲5.820 | ▲1.625 |
| Price To Free Cash Flow Ratio | -0.873 | ▼-0.083 | ▲5.279 |
| Price To Operating Cash Flow Ratio | -0.873 | ▼-0.079 | ▲6.562 |
| Debt To Assets Ratio | 0.124 | ▲0.033 | ▲0.045 |
| Debt To Equity Ratio | 1.182 | ▲0.847 | ▲0.749 |
| Debt To Capital Ratio | 0.542 | ▲0.291 | ▲0.277 |
| Long Term Debt To Capital Ratio | 0.233 | ▲0.164 | ▲0.173 |
| Financial Leverage Ratio | 9.568 | ▲5.874 | ▲4.712 |
| Working Capital Turnover Ratio | 0.085 | ▼-0.208 | ▼-0.158 |
| Operating Cash Flow Ratio | -2.648 | ▼-0.809 | ▼-1.928 |
| Operating Cash Flow Sales Ratio | -8.745 | ▼-6.458 | ▼-6.417 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.005 | ▼-0.042 |
| Debt Service Coverage Ratio | -364.120 | ▼-364.120 | ▼-291.296 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | -502.817 | ▼-502.817 | ▼-402.254 |
| Operating Cash Flow Coverage Ratio | -5.079 | ▲0.328 | ▼-3.196 |
| Capital Expenditure Coverage Ratio | -4488.561 | ▼-4305.370 | ▼-3556.143 |
| Dividend Paid And Capex Coverage Ratio | -4488.561 | ▼-4305.370 | ▼-3556.143 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -0.985 | ▲0.760 | ▲11.563 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $160.7M | $182.6M | $668.2M | $761.2M | $1.66B | |
| Enterprise value | $131.1M | $192.0M | $632.6M | $650.2M | $1.38B | |
| EV / Sales | 6.23x | 1.91x | 6.52x | 4.87x | 6.66x | |
| EV / Op. cash flow | -0.71x | -0.83x | -3.44x | -31.98x | 4.62x | |
| EV / Free cash flow | -0.71x | -0.83x | -3.39x | -26.60x | 4.67x | |
| EV / EBITDA | -0.98x | -1.75x | -5.44x | -5.35x | -49.23x | |
| Net debt / EBITDA | 0.22x | -0.09x | 0.31x | 0.91x | 10.05x | |
| Current ratio | 3.83x | 3.40x | 3.18x | 7.74x | 5.37x | |
| Income quality | 1.29x | 1.93x | 1.41x | 0.15x | -8.22x | |
| Graham net-net | -$0 | $1 | $1 | $2 | $3 | |
| Tax burden | 100.1% | 100.1% | 104.2% | 102.5% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $196.9M | $299.8M | $387.9M | $632.6M | $610.2M | |
| Invested capital | $221.5M | $336.9M | $434.9M | $686.0M | $668.1M | |
| Return on assets | -48.7% | -25.4% | -21.0% | -16.9% | -4.5% | |
| Operating ROA | -38.3% | -26.6% | -21.5% | -17.2% | -5.7% | |
| Return on tangible assets | -48.7% | -25.4% | -21.0% | -16.9% | -4.5% | |
| Return on equity | -466.3% | -93.9% | -97.2% | -62.2% | -12.1% | |
| Return on invested capital | -62.5% | -41.2% | -33.5% | -19.6% | -5.5% | |
| Return on capital employed | -65.2% | -42.2% | -34.2% | -19.9% | -5.5% | |
| Earnings yield | -89.0% | -65.2% | -19.5% | -17.5% | -2.2% | |
| Free cash flow yield | -114.6% | -126.6% | -27.9% | -3.2% | 17.8% | |
| Capex / Op. cash flow | -0.0% | -0.5% | -1.3% | -20.3% | 1.1% | |
| Capex / Depreciation | 0.4% | 14.2% | 26.9% | 48.6% | 39.0% | |
| Capex / Sales | 0.2% | 1.2% | 2.5% | 3.1% | 1.6% | |
| SG&A / Sales | 256.5% | 57.1% | 58.4% | 45.7% | 26.6% | |
| R&D / Sales | 584.8% | 208.1% | 197.9% | 157.5% | 91.5% | |
| Stock comp / Sales | 126.7% | 39.2% | 44.1% | 34.5% | 19.7% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 7d | 13d | |
| Days payables outstanding | 64d | 4d | 156d | 0d | 9d | |
| Operating cycle | 0d | 0d | 0d | 7d | 13d | |
| Cash conversion cycle | -64d | -4d | -156d | 7d | 4d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-12.0%EV / Sales ▲+226.2%EV / EBITDA ▲+43.5%EV / Op. cash flow ▲+0.123Earnings yield ▼-0.237
Profitability
Return on equity ▼-3.725Return on assets ▼-0.233Return on invested capital ▼-0.213Return on capital employed ▼-0.229Operating ROA ▼-0.117Income quality ▼-0.644Tax burden +0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▲+59.539Operating cycle n/aCash conversion cycle ▼-59.539Capex / Sales ▼-0.011R&D / Sales ▲+3.767
Balance-sheet strength
Current ratio ▲+0.437Net debt / EBITDA ▲+0.308Working capital ▼-102809000.000Invested capital ▼-115352000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-90.3%EV / Sales ▼-6.4%EV / EBITDA ▲+98.0%EV / Op. cash flow ▼-5.332Earnings yield ▼-0.868
Profitability
Return on equity ▼-4.543Return on assets ▼-0.443Return on invested capital ▼-0.571Return on capital employed ▼-0.596Operating ROA ▼-0.326Income quality ▲+9.506Tax burden ▲+0.001
Efficiency
Days sales outstanding ▼-13.027Days payables outstanding ▲+54.736Operating cycle ▼-13.027Cash conversion cycle ▼-67.763Capex / Sales ▼-0.014R&D / Sales ▲+4.933
Balance-sheet strength
Current ratio ▼-1.538Net debt / EBITDA ▼-9.828Working capital ▼-413209000.000Invested capital ▼-446555000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-08 Comparing Alector (NASDAQ:ALEC) and Sarepta Therapeutics (NASDAQ:SRPT) Alector (NASDAQ: ALEC - Get Free Report) and Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation. Profitability This table compares Alector and Sarepta Therapeutics'' net
- 2026-09-03 Alector to Participate in Upcoming Healthcare Conferences SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026 (New York, New York) Thursday, September 10, 2026, at 2:10 p.m.
- 2026-08-06 Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates Alector (ALEC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.3 per share a year ago.
- 2026-08-06 Alector Reports Second Quarter 2026 Financial Results and Provides Business Update Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector''s lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer''s disease (AD). Continued progress across AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) and AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson''s disease (PD)).
- 2026-07-08 Alector and GSK partnership to end after dementia, Alzheimer''s drug failures Alector said on Wednesday that GSK had terminated their neuroscience collaboration agreement covering two experimental antibody drugs after both the drug candidates suffered clinical setbacks.